Nitric oxide negatively regulates c-Jun N-terminal kinase/stress-activated protein kinase by means of S-nitrosylation

Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14382-7. doi: 10.1073/pnas.97.26.14382.

Abstract

NO, produced from l-arginine in a reaction catalyzed by NO synthase, is an endogenous free radical with multiple functions in mammalian cells. Here, we demonstrate that endogenously produced NO can suppress c-Jun N-terminal kinase (JNK) activation in intact cells. Treatment of BV-2 murine microglial cells with IFN-gamma induced endogenous NO production, concomitantly suppressing JNK1 activation. Similarly, IFN-gamma induced suppression of JNK1 activation in RAW264.7 murine macrophage cells and rat alveolar macrophages. The IFN-gamma-induced suppression of JNK1 activation in BV-2, RAW264.7, or rat alveolar macrophage cells was completely prevented by N(G)-nitro-l-arginine, a NO synthase inhibitor. Interestingly, the IFN-gamma-induced suppression of JNK1 activation was not affected by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one, an inhibitor of guanylyl cyclase. 8-Bromo-cGMP, a membrane-permeant analogue of cGMP, did not change JNK1 activation in intact cells either. In contrast, S-nitro-N-acetyl-dl-penicillamine (SNAP), a NO donor, inhibited JNK1 activity in vitro. Furthermore, a thiol reducing agent, DTT, reversed not only the in vitro inhibition of JNK1 activity by SNAP but also the in vivo suppression of JNK1 activity by IFN-gamma. Substitution of serine for cysteine-116 in JNK1 abolished the inhibitory effect of IFN-gamma or SNAP on JNK1 activity in vivo or in vitro, respectively. Moreover, IFN-gamma enhanced endogenous S-nitrosylation of JNK1 in RAW264.7 cells. Collectively, our data suggest that endogenous NO mediates the IFN-gamma-induced suppression of JNK1 activation in macrophage cells by means of a thiol-redox mechanism.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line
  • Cells, Cultured
  • Cyclic GMP / metabolism
  • Cysteine / metabolism
  • Enzyme Activation
  • Humans
  • Interferon-gamma / metabolism
  • Interferon-gamma / pharmacology
  • JNK Mitogen-Activated Protein Kinases
  • MAP Kinase Kinase 4*
  • MAP Kinase Kinase Kinase 1*
  • Macrophages / cytology
  • Macrophages / drug effects
  • Male
  • Mice
  • Mitogen-Activated Protein Kinase 8
  • Mitogen-Activated Protein Kinase Kinases
  • Mitogen-Activated Protein Kinases / metabolism*
  • Nitric Oxide / metabolism*
  • Nitric Oxide Donors / metabolism*
  • Nitric Oxide Donors / pharmacology
  • Oxidation-Reduction
  • Penicillamine / analogs & derivatives*
  • Penicillamine / metabolism*
  • Penicillamine / pharmacology
  • Protein Serine-Threonine Kinases / metabolism
  • Rats
  • Rats, Sprague-Dawley
  • Sulfhydryl Compounds / metabolism

Substances

  • Nitric Oxide Donors
  • S-nitro-N-acetylpenicillamine
  • Sulfhydryl Compounds
  • Nitric Oxide
  • Interferon-gamma
  • Protein Serine-Threonine Kinases
  • JNK Mitogen-Activated Protein Kinases
  • Mitogen-Activated Protein Kinase 8
  • Mitogen-Activated Protein Kinases
  • MAP Kinase Kinase Kinase 1
  • MAP3K1 protein, human
  • Map3k1 protein, mouse
  • MAP Kinase Kinase 4
  • MAP2K4 protein, human
  • Map2k4 protein, mouse
  • Mitogen-Activated Protein Kinase Kinases
  • Penicillamine
  • Cyclic GMP
  • Cysteine